Alleviant Medical develops a no-implant shunt therapy designed to alleviate the clinical and economic burden of heart failure. The Alleviant System, which has received Breakthrough Device Designation from the U.S. FDA, aims to improve patient outcomes and reduce healthcare costs associated with heart failure management.
Funding
$188.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
GHFounders
Product
Problem
Heart failure patients often experience fluid overload, leading to increased pressure in the heart and lungs, which results in shortness of breath, fatigue, and reduced quality of life. Current treatment options, such as medication and lifestyle changes, may not adequately address these issues, and more invasive procedures like heart transplants carry significant risks.
Solution
Alleviant Medical is developing a novel, no-implant shunt therapy designed to alleviate the clinical and economic burden of heart failure. The Alleviant System aims to reduce pressure in the heart and lungs by creating a pathway for excess fluid to be redirected, thereby improving patient outcomes and reducing healthcare costs associated with heart failure management. This minimally invasive approach seeks to provide a safe and effective alternative for patients who have not found sufficient relief through traditional methods. The system is currently undergoing clinical trials to evaluate its safety and efficacy.
Target Audience
The primary target audience includes heart failure patients who are not adequately managed with current therapies and physicians specializing in cardiology and heart failure management.
Features
- No-implant shunt therapy, avoiding the risks associated with implanted devices.
- Minimally invasive procedure, potentially reducing recovery time and complications.
- Designed to reduce pressure in the heart and lungs, alleviating symptoms of heart failure.
- Aims to improve patient outcomes and quality of life.
- Currently undergoing clinical trials (ALLAY-HF trial) to evaluate safety and efficacy.
- Has received Breakthrough Device Designation from the U.S. FDA.